企業プロフィール
HOOKIPA Pharma Inc. 株価・ニュース・カタリスト
- ティッカー:
- HOOK
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
1.15 USD (+0.88%)
終値
最終更新: 2026年6月2日
—
時価総額
株価変動の要因
HOOK の終値変動に関する情報は現在取得できません。
企業概要
Arenaviral Immunotherapy Platform
HOOKIPA Pharma develops immunotherapies using engineered arenavirus vectors designed to generate strong antigen-specific T-cell responses. The platform supports both oncology programs and partnered infectious-disease vaccines.
HB-700 for KRAS-Mutated Cancers
HB-700 is a multi-antigen therapy directed at common KRAS mutations across lung, colorectal, pancreatic, and other cancers. The program uses repeated administration of complementary vectors to sustain immune activity against tumor antigens.
Clinical Proof from Eseba-Vec
The HB-700 strategy is supported by clinical experience with eseba-vec, formerly HB-200, in HPV16-positive head and neck cancer. That program demonstrated the platform's ability to induce antigen-specific immune responses in patients with advanced cancer.
Partnered Infectious-Disease Programs
HOOKIPA has collaborated with Gilead on arenaviral immunotherapies for hepatitis B and HIV. Partner funding and milestone economics provide a second business model alongside internally led oncology development.
Portfolio Prioritization
The company has paused or divested selected programs to focus capital on its highest-priority assets and collaborations. Its development model relies on specialized vector engineering, outsourced manufacturing, and external clinical networks.
今後のカタリスト
- Interim Phase 1 data from HB-700 in KRAS-mutated cancers in the first half of 2026.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。